A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2032-10-31
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe Chronic Obstructive Pulmonary Disease（COPD）.
The study has two parts. Each part consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 8-week safety follow-up period.